These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28866646)

  • 1. High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA).
    Bonekamp N; Caorsi R; Viglizzo GM; Graaf M; Minoia F; Grossi A; Picco P; Ceccherini I; Frenkel J; Gattorno M
    Ann Rheum Dis; 2018 Aug; 77(8):1241-1243. PubMed ID: 28866646
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
    Arakawa A; Ruzicka T; Prinz JC
    JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel use of Autoinflammatory Diseases Activity Index (AIDAI) captures skin and extracutaneous features to help manage pediatric DITRA: A case report and a proposal for a modified disease activity index in autoinflammatory keratinization disorders.
    Stephenson C; Prajapati VH; Hunter C; Miettunen P
    Pediatr Dermatol; 2020 Jul; 37(4):670-676. PubMed ID: 32301172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab as therapy for psoriasis in a 2-year-old girl.
    Min MS; Shroff A; Rose S; Lebwohl M; Guttman-Yassky E
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e109-e110. PubMed ID: 26377248
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
    Jack C; Mashiko S; Arbour N; Bissonnette R; Sarfati M
    Br J Dermatol; 2017 Jul; 177(1):267-270. PubMed ID: 27599204
    [No Abstract]   [Full Text] [Related]  

  • 6. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 7. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
    Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
    Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent response to ustekinumab in a 9-year-old girl with severe psoriasis.
    González-Barreto RM; Rochet NM; Nevares-Pomales OW; Colón-Fontanez F
    Pediatr Dermatol; 2018 Jan; 35(1):e76-e78. PubMed ID: 29205479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
    Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
    [No Abstract]   [Full Text] [Related]  

  • 10. Clearance of annular pustular psoriasis with ustekinumab.
    Schnabel V; Broekaert SMC; Schön MP; Mössner R
    Eur J Dermatol; 2017 Jun; 27(3):296-297. PubMed ID: 28202422
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of severe psoriasis in an adolescent with ustekinumab.
    AbuHilal M; Ho N
    Pediatr Dermatol; 2015; 32(3):377-80. PubMed ID: 25727845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of superimposed linear psoriasis to ustekinumab: A case report.
    Weng HJ; Tsai TF
    Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist.
    Sugiura K; Endo K; Akasaka T; Akiyama M
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2054-6. PubMed ID: 24910924
    [No Abstract]   [Full Text] [Related]  

  • 15. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
    Vergou T; Moustou AE; Antoniou C
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
    Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
    J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of ustekinumab in palmoplantar pustulosis.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Uthurriague C; Paul C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e204-e206. PubMed ID: 29194805
    [No Abstract]   [Full Text] [Related]  

  • 18. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
    Fujita Y; Shinkuma S; Nomura T; Shimizu H
    Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
    [No Abstract]   [Full Text] [Related]  

  • 20. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.